Cargando…

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile

Substantial proportion of Crohn's disease (CD) patients shows no response or a limited response to treatment with infliximab (IFX) and to identify biomarkers of response would be of great clinical and economic benefit. The expression profile of five genes (S100A8-S100A9, G0S2, TNFAIP6, and IL11...

Descripción completa

Detalles Bibliográficos
Autores principales:	Medrano, Luz María, Taxonera, Carlos, González-Artacho, Cristina, Pascual, Virginia, Gómez-García, María, Barreiro-de Acosta, Manuel, Pérez-Calle, José L., Bermejo, Fernando, López-Sanromán, Antonio, Martín Arranz, Dolores, Gisbert, Javier P., Mendoza, Juan Luis, Martín, Javier, Núñez, Concepción, Urcelay, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539178/ https://www.ncbi.nlm.nih.gov/pubmed/26339133 http://dx.doi.org/10.1155/2015/318207

Ejemplares similares

Management and outcomes of patients with Crohn’s disease with first vs multiple surgeries: results from the PRACTICROHN study
por: Iborra, Marisa, et al.
Publicado: (2019)

CD209 in inflammatory bowel disease: a case-control study in the Spanish population
por: Núñez, Concepción, et al.
Publicado: (2007)

Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
por: Chaparro, María, et al.
Publicado: (2019)

Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
por: Guijarro, Luis G., et al.
Publicado: (2022)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review
por: Barreiro-de Acosta, Manuel, et al.
Publicado: (2023)

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
por: Martínez-Feito, Ana, et al.
Publicado: (2020)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?
por: Cerna, Karin, et al.
Publicado: (2023)

Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease()()
por: Garcia, Lucas Campos, et al.
Publicado: (2021)

Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease
por: Kamel, Amir Y., et al.
Publicado: (2016)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
por: Gisbert, Javier P., et al.
Publicado: (2023)

Demodicosis as an opportunistic infection in a patient with Crohn’s disease treated with infliximab
por: Niedźwiedź, Michał, et al.
Publicado: (2022)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Infliximab-induced intertriginous psoriasis in patient with Crohn's disease
por: Mola, Federica, et al.
Publicado: (2011)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy
por: Timmermans, Wilhelmina M. C., et al.
Publicado: (2016)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Infliximab-Induced Aseptic Meningitis in a Patient with Crohn’s Disease
por: Junga, Zachary, et al.
Publicado: (2018)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
por: Chiba, Mitsuro, et al.
Publicado: (2019)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Optimized timing of using infliximab in perianal fistulizing Crohn's disease
por: Sun, Xue-Liang, et al.
Publicado: (2020)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
por: Razmeh, Saeed, et al.
Publicado: (2021)

Brain Abscesses in Crohn’s Disease as a Complication of Infliximab Therapy
por: Mansour, Mahmoud M, et al.
Publicado: (2021)

Proactive measurement of infliximab drug levels in children with Crohn’s disease
por: Holland, Kathleen, et al.
Publicado: (2022)

The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
por: Li, Shuyan, et al.
Publicado: (2023)

Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn’s disease: analysis from the PRACTICROHN study
por: Gutiérrez, Ana, et al.
Publicado: (2019)

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study
por: Chaparro, María, et al.
Publicado: (2022)

Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
por: Rubín de Célix, Cristina, et al.
Publicado: (2022)

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0pfbbsub477u96fpbcq2mggs9b